A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1A.
Abroad (travel likely)RecruitingPHASE1
Conditions
Charcot-Marie-Tooth Disease, Type 1A
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
The Ottawa Hospital, Ottawa, Ontario, Canada
Contact: Principal Investigator (Alberto Aleman)Montreal Neurological Institute, Montreal, Quebec, Canada
Contact: Principal Investigator (Rami Massie)CIUSS de l´Estrie-CHUS- Hôpital Fleurimont, Sherbrooke, Quebec, Canada
Contact: Study coordinator (Caroline Cayer) · caroline.cayer.ciussse-chus@ssss.gouv.qc.ca · 1-819-346-1110Contact: Principal Investigator (Marie-France Rioux)